Quarterly report · Q2
3034.TEDINET S100PL5A
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥82.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥166.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥81.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥4.0bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥4.2bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥4.2bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥10.1bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.3bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥4.2bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥4.3bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.5bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥2.5bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥91.0bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥96.0bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥97.6bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥45.1bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥52.1bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥45.9bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥43.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥41.1bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥14.5bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥16.7bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥14.3bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥16.5bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥16.2bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥19.5bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥4.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥10.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.6bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥5.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥10.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥4.1bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥64.11 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥36.92 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥149.51 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥66.98 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥38.76 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 50.4% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.7% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.1% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥181m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥181m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥1.7bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥75.6bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥75.6bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥58m |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥5.1bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥7.0bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥6.9bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥123m |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥645m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥82.6bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥82.5bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥181m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥5.7bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥193m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥193m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥1.7bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥75.4bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥75.3bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥40m |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥5.2bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥6.6bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥6.5bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥153m |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥663m |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥82.0bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥81.8bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥193m |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥5.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 524
| Item | Context | Value | Unit |
|---|---|---|---|
| Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cf | Prior1YTDDuration | -2845000000 | JPY |
| Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cf | CurrentYTDDuration | － | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -527000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -527000000 | JPY |
| Proceeds from sale and leaseback fin cf | Prior1YTDDuration | － | JPY |
| Proceeds from sale and leaseback fin cf | CurrentYTDDuration | 138000000 | JPY |
| Other net fin cf | Prior1YTDDuration | -2000000 | JPY |
| Other net fin cf | CurrentYTDDuration | -4000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -4125000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -5223000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -3262000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -2193000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 19498000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 16516000000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 16236000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 14323000000 | JPY |
| Payroll and allowances sga | Prior1YTDDuration | 1345000000 | JPY |
| Payroll and allowances sga | CurrentYTDDuration | 1468000000 | JPY |
| Provision for bonuses personnel expenses | Prior1YTDDuration | 122000000 | JPY |
| Provision for bonuses personnel expenses | CurrentYTDDuration | 148000000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 34000000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 32000000 | JPY |
| Amortization of goodwill el | Prior1YTDDuration | 1569000000 | JPY |
| Amortization of goodwill el | CurrentYTDDuration | 1583000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E03476-000HealthInsurancePharmacyReportableSegmentsMember | 75341000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E03476-000MedicalRelatedReportableSegmentMember | 6473000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 81814000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 81814000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E03476-000HealthInsurancePharmacyReportableSegmentsMember | 40000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E03476-000MedicalRelatedReportableSegmentMember | 153000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 193000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -193000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E03476-000HealthInsurancePharmacyReportableSegmentsMember | 75381000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E03476-000MedicalRelatedReportableSegmentMember | 6626000000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 82008000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -193000000 | JPY |
| Net sales | Prior1YTDDuration | 81814000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E03476-000HealthInsurancePharmacyReportableSegmentsMember | 5181000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E03476-000MedicalRelatedReportableSegmentMember | 663000000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 5844000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -1666000000 | JPY |
| Operating income | Prior1YTDDuration | 4177000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E03476-000HealthInsurancePharmacyReportableSegmentsMember | 75557000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E03476-000MedicalRelatedReportableSegmentMember | 6901000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 82459000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 82459000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E03476-000HealthInsurancePharmacyReportableSegmentsMember | 58000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |